ABSTRACT: Positron-emission tomography (PET) scan is a widely used imaging modality in the management of various malignancies. There is considerable controversy regarding its use in breast cancer diagnosis and treatment. In this review, we discuss published data on the use of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG-PET) in the staging workup of locally advanced breast cancer, and management of locally recurrent and metastatic breast cancer. FDG-PET is a useful tool in staging advanced breast cancer and assessing the extent of disease involvement when metastasis is suspected. It might also aid in assessing early response to therapy. Future goals of improving PET scan accuracy in the management of breast cancer will be achieved through utilizing radiotracers, based on a better understanding of tumor biology and improvement in breast-specific PET scans.
In 2008, more than 184,000 new patients were diagnosed with breast cancer, the most commonly diagnosed malignancy in women in the United States. Despite great advances over the past few years in screening, detection, and treatment, more than 40,000 women died from the disease in 2008. Early breast cancer is considered a curable disease, but the curative potential of patients with locally advanced or metastatic disease is limited.
Imaging in Breast Cancer
Various imaging modalities have contributed to the evolution of breast cancer care. Early detection by mammography is a key element in the improvement of survival in breast cancer patients. Ultrasonography is frequently used to differentiate benign cysts from solid lesions, and to assess axillary lymph node involvement. It also serves as a localizing imaging modality when biopsy is recommended. Magnetic resonance imaging (MRI) of the breast yields better visualization of denser breasts and the chest wall, and is currently recommended for women who are at high risk for developing breast cancer (eg, those with a strong family history or known inherited susceptibility to the disease).
In this review, we focus on the role of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG)-PET in the diagnosis and management of breast cancer. FDG is a radioactive glucose analog with a short half-life. Tumor cells have a rapid growth rate and thus utilize more glucose. When a patient is injected with FDG, it is taken by these tumor cells, but not metabolized. The proportion of FDG trapping is dependent on the rate of glucose metabolism. The level of uptake is quantified and reported as a standardized uptake value (SUV).[5,6] FDG is given intravenously 1 hour before the scan in a very small dose, which has no pharmacologic effect. To avoid false-positives due to elevated blood glucose levels, the patient is asked to fast overnight and a normal blood glucose level must be documented.
FDG-PET has the advantage of providing functional information compared with just the anatomic characterization provided by conventional imaging studies. FDG-PET is used for diagnostic staging, recurrence evaluation, and to assess response to therapy in multiple malignancies. A strong body of clinical evidence supports its use in non–small-cell lung cancer, Hodgkin and aggressive non-Hodgkin lymphoma, colorectal carcinoma, and melanoma. Its role in advanced nonmetastatic, locally recurrent, and metastatic breast cancer will be discussed in this review.
Since 2005, PET/computed tomography (CT) fusion scanners have largely replaced traditional PET scans with the promise of better ability to detect cancer and lower false-positive rates. PET/CT fusion studies have the advantage of anatomic characterization in addition to the functional information provided by PET.[9,10] Furthermore, it would be less likely to mistake the normal physiologic accumulation seen in some PET studies when no corresponding lesion is observed on the CT portion.
Improvement in the knowledge of cancer biology and its metabolic pathways has led to the utilization of other metabolic radiotracers in PET scans. 16b-[18F]-Fluoro-17b-estradiol (FES) is an estrogen receptor (ER) ligand used for the detection of ER-positive breast cancer. Patients with higher FES uptake and metabolic flare after estradiol challenge were more likely to respond to endocrine treatment and had a better overall survival in a recent study. Another radiotracer that has been evaluated in ER-positive breast cancers is carbon-11–labeled tetrahydroisoquinoline derivative, which is a selective estrogen receptor modulator.
Hypoxia is associated with more aggressive tumors as well as resistance to chemotherapy and radiation in some cancers. 18F-labeled fluoromisonidazole (FMISO) is a radiotracer that measures tissue hypoxia, and is currently being studied in breast cancer.
Breast Positron-Emission Mammography
Positron-emission mammography (PEM) is a new technology that was developed to overcome the limitation of whole-body PET in detecting smaller breast lesions and to improve visualization of fibrodense breast tissue and breasts with fibrocystic disease. With PEM, two high-resolution detector heads are placed on opposite sides of a compressed breast, and the data is integrated with conventional mammography. PEM has shown promising results in detecting primary ductal carcinoma in situ and recurrent breast disease, as well as for directing biopsy of suspicious lesions.[15,16]
Role of PET Scan in Early-Stage Breast Cancer
The role of FDG-PET in the routine workup and management of early breast cancer remains limited due to its low sensitivity in detecting smaller tumors and the high cost. In a large prospective clinical series (N = 144), the sensitivity of detecting tumors more than 1 cm in diameter was 91%, but the sensitivity dropped to 57% when looking at tumors smaller than 1 cm, and to 25% when looking at carcinoma in situ.
On the other hand, FDG-PET might provide information about the growth pattern and prognosis of primary breast cancer. In a clinical study by Crippa et al, higher SUV values were associated with higher histologic grades and cellular proliferation. In another clinical trial of 70 patients, higher uptake was associated with a statistically worse relapse-free and overall survival. Nevertheless, there is no consensus on how to utilize this information.
Axillary Lymph Node Staging
Tumor involvement in the axilla has a significant prognostic value in disease survival and recurrence in breast cancer. FDG-PET sensitivity in detecting axillary node involvement appears to vary—from as low as 20% in some studies to as high as 100%—but the specificity remains relatively high at 85% to 100% (Table 1).[20-23] In an older study (N = 124), FDG-PET scan detected axillary nodal disease in all of 44 patients but with a high false-positive rate. In a more recent multicenter prospective study (N = 308), however, FDG-PET had a sensitivity of 61% with a specificity of 80% in detecting axillary lymph node involvement. Another clinical trial showed that sensitivity appears to improve with higher-stage lymph node involvement (for pN1, 41%; pN2, 67%; and pN3, 100%). Sentinel lymph node biopsy seems to have a higher sensitivity and remains the standard of care for diagnosing axillary lymph node involvement.
Internal Mammary Nodes
Internal mammary node involvement occurs in approximately 25% of patients at the time of diagnosis and is usually associated with a worse outcome. These nodes are not routinely biopsied due to their inaccessibility. FDG-PET is more sensitive in detecting internal mammary nodes than conventional CT, as evidenced by a study that showed a sensitivity of 85% compared to 50% with CT with pathologic confirmation.
Metastatic Workup for Locally Advanced Breast Cancer
Bone scintigraphy is currently the most commonly used method to investigate bone metastasis. However, other inflammatory conditions such as degenerative arthritis, fractures, and Paget’s disease might lead to false-positive bone scintigraphy findings. Ohta et al compared PET scan with bone scintigraphy in 51 patients with bone metastatsis. PET had a similar sensitivity to bone scintigraphy (78%), but had a better specificity (98% vs 81%).
FDG-PET might have an advantage over bone scan by visualizing the metabolic activity of tumor cells rather than detecting the osteoblastic response to destruction by these cells. For example, FDG-PET has a superior ability to detect osteolytic bony lesions, which have a greater metabolic activity. These lesions are associated with more aggressive disease and a worse prognosis. Moreover, bone scans are positive when there is an osteoblastic response, and thus, they might remain positive even after successful treatment. Nonetheless, FDG-PET scan appears to have a lower rate of sensitivity compared to bone scan in detecting osteoblastic lesions. Taking all of these data into account, it appears that the role of FDG-PET scan is to complement the information obtained from a bone scan rather than replace it.
Evaluating for distant visceral metastasis is an essential element of the complete workup in patients with locally advanced breast cancer or worrisome symptoms. Current imaging modalities that are being used to evaluate for distant metastasis include ultrasonography, computed tomography, and bone scintigraphy.
Dose et al compared FDG-PET with conventional imaging studies to detect distant metastases in 50 breast cancer patients. FDG-PET had a sensitivity of 86% and a specificity of 86%, compared with 36% and 95% for conventional imaging. FDG-PET was superior in detecting pulmonary and mediastinal lymph node metastasis compared to chest x-ray, but was comparable in detecting bone and liver metastases compared with bone scinitigraphy and ultrasound of the abdomen. Another recent study looked at 119 patients with clinical suspicion for metastatic disease (69 patients with newly diagnosed locally advanced disease and 50 patients with a previous history of breast cancer). These investigators found that FDG-PET had a sensitivity of 87% and a specificity of 83% compared with 43% and 98%, respectively, for conventional imaging.
Furthermore, FDG-PET can potentially alter the staging of advanced breast cancer. A retrospective study of 125 patients with advanced breast cancer who underwent PET and conventional imaging showed that PET scan resulted in a change of the clinical stage in 67% of patients (43% upstaged and 24% downstaged). In 32% of patients, this resulted in a change in treatment plan. In another clinical study of 175 patients with locoregional recurrence, FDG-PET detected distant metastasis in 16% of patients; 24% had evidence of distant metastasis within 18 months.
FDG-PET appears to have a limited role in detecting brain metastases due to the high uptake in surrounding tissue. However, combined PET/CT studies with contrast enhancement appear to have a better sensitivity in detecting these lesions. MRI of the brain and CT with contrast enhancement remain the standard diagnostics studies in detecting brain metastases.
1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. Elmore JG, Armstrong K, Lehman CD, et al: Screening for breast cancer. JAMA 293:1245-1256, 2005.
3. Prasad SN, Houserkova D: The role of various modalities in breast imaging. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151:209-218, 2007.
4. Swayampakula AK, Dillis C, Abraham J: Role of MRI in screening, diagnosis and management of breast cancer. Expert Rev Anticancer Ther 8:811-817, 2008.
5. Endo K, Oriuchi N, Higuchi T, et al: PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 11:286-296, 2006.
6. Quon A, Gambhir SS: FDG-PET and beyond: Molecular breast cancer imaging. J Clin Oncol 23:1664-1673, 2005.
7. Blodgett TM, McCook BM, Federle MP: Positron emission tomography/computed tomography: protocol issues and options. Semin Nucl Med 36:157-168, 2006.
8. Fletcher JW, Djulbegovic B, Soares HP, et al: Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480-508, 2008.
9. Zangheri B, Messa C, Picchio M, et al: PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 31(suppl 1):S135-S142, 2004.
10. Hayashi M, Murakami K, Oyama T, et al: PET/CT supports breast cancer diagnosis and treatment. Breast Cancer 15:224-230, 2008.
11. Lim H,Yoon W, Chung T, et al: FDG PET/CT for the detection and evaluation of breast diseases: Usefulness and limitations. RadioGraphics 27:S197–S213, 2007.
12. Dehdashti F, Mortimer JE, Trinkaus K, et al: PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113:509-517, 2008.
13. Gao M, Wang M, Miller KD, et al: Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer. Eur J Med Chem 43:2211-2219, 2008.
14. Rajendran JG, Mankoff DA, O’Sullivan F, et al: Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245-2252, 2004.
15. Schilling K, Conti P, Adler L, et al: The role of positron emission mammography in breast cancer imaging and management. Appl Radiol 37:26-36, 2008.
16. Tafra L: Positron emission tomography (PET) and mammography (PEM) for breast cancer: Importance to surgeons. Ann Surg Oncol 14:3-13, 2007.
17. Avril N, Rosé CA, Schelling M, et al: Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495-3502, 2000.
18. Crippa F, Seregni E, Agresti R, et al: Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation. Eur J Nucl Med 25:1429-1434, 1998.
19. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 82:2227-2234, 1998.
20. Hodgson NC, Gulenchyn KY: Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 26:712-720, 2008.
21. Eubank WB, Mankoff DA: Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35:84-99, 2005.
22. Ohta M, Tokuda Y, Saitoh Y, et al: Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer. Breast Cancer 7:99-103, 2000.
23. Veronesi U, De Cicco C, Galimberti VE, et al: A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473-478, 2007.
24. Utech CI, Young CS, Winter PF: Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23:1588-1593, 1996.
25. Wahl RL, Siegel BA, Coleman RE, et al; PET Study Group: Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET Study Group. J Clin Oncol 22:277-285, 2004.
26. Cermik TF, Mavi A, Basu S, et al: Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 35:475-483, 2008.
27. Crippa F, Gerali A, Alessi A, et al: FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging 31(suppl 1):S97-S102, 2004.
28. Eubank WB, Mankoff DA, Takasugi J, et al: 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19:3516-3523, 2001.
29. Fogelman I, Cook G, Israel O, et al: Positron emission tomography and bone metastases. Semin Nucl Med 35:135-142, 2005.
30. Ohta M, Tokuda Y, Suzuki Y, et al: Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22:875-879, 2001.
31. Buscombe JR, Holloway B, Roche N, et al: Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging 48:109-118, 2004.
32. Byrne AM, Hill AD, Skehan SJ, et al: Positron emission tomography in the staging and management of breast cancer. Br J Surg 91:1398-1409, 2004.
33. Dose J, Bleckmann C, Bachmann S, et al: Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Commun 23:857-864, 2002.
34. Mahner S, Schirrmacher S, Brenner W, et al: Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19:1249-1254, 2008.
35. Segaert I, Neven P, Ceyssens S, et al: preoperative FDG-PET/ CT can change the tumor stage in locally advanced breast cancer (abstract 5014). Breast Cancer Res Treat 94(suppl 1), 2005.
36. Eubank WB, Mankoff D, Bhattacharya M, et al: Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 183:479-486, 2004.
37. van Oost FJ, van der Hoeven JJ, Hoekstra OS, et al: Staging in patients with locoregionally recurrent breast cancer: Current practice and prospects for positron emission tomography.Eur J Cancer 40:1545-1553, 2004.
38. Kitajima K, Nakamoto Y, Okizuka H, et al: Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 22:595-602, 2008.
39. Goerres GW, Michel SC, Fehr MK, et al: Follow-up of women with breast cancer: Comparison between MRI and FDG PET. Eur Radiol 13:1635-1644, 2003.
40. Landheer ML, Steffens MG, Klinkenbijl JH, et al: Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg 92:1363-1367, 2005.
41. Hathaway PB, Mankoff DA, Maravilla KR, et al: Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 210:807-814, 1999.
42. Ahmad A, Barrington S, Maisey M, et al: Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 79:478-482, 1999.
43. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997.
44. Prati R, Minami CA, Gornbein JA, et al: Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer Jan 20, 2009 (epub ahead of print).
45. Schwarz-Dose J, Untch M, Tiling R, et al: Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 27:535-541, 2009.
46. Rousseau C, Devillers A, Sagan C, et al: Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.J Clin Oncol 24:5366-5372, 2006.
47. Smith IC, Welch AE, Hutcheon AW, et al: Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000.
48. Burcombe RJ, Makris A, Pittam M, et al: Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 38:375-379, 2002.
49. Mortimer JE, Dehdashti F, Siegel BA, et al: Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797-2803, 2001.
50. Cachin F, Prince HM, Hogg A, et al: Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.J Clin Oncol 24:3026-3031, 2006.
51. Couturier O, Jerusalem G, N’Guyen JM, et al: Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 12:6437-6443, 2006.
52. Lonneux M, Borbath I I, Berlière M, et al: The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45-49, 2000.
53. Saad A, Abraham J: Role of tumor markers and circulating tumors cells in the management of breast cancer. Oncology (Williston Park) 22:726-744 (incl discussion), 2008.
54. Gil-Rendo A, Zornoza G, García-Velloso MJ, et al: Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93:707-712, 2006.
55. Zornoza G, Garcia-Velloso MJ, Sola J, et al: 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 30:15-19, 2004.
56. Greco M, Crippa F, Agresti R, et al: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst 93:630-635, 2001.
57. Schirrmeister H, Kühn T, Guhlmann A, et al: Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures. Eur J Nucl Med 28:351-358, 2001.
58. Crippa F, Agresti R, Seregni E, et al: Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 39:4-8, 1998.
59. Kumar R, Zhuang H, Schnall M, et al: FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 27:231-236, 2006.
60. Lovrics PJ, Chen V, Coates G, et al: A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11:846-853, 2004.
61. van der Hoeven JJ, Hoekstra OS, Comans EF, et al: Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619-624, 2002.
62. Adler LP, Faulhaber PF, Schnur KC, et al: Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203:323-327, 1997.
63. Avril N, Dose J, Jänicke F, et al: Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 88:1204-1209, 1996.
64. Chung A, Liou D, Karlan S, et al: Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg 141:783-788, 2006.
65. Smith IC, Ogston KN, Whitford P, et al: Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 228:220-227, 1998.
66. Bender H, Kirst J, Palmedo H, et al: Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17(3B):1687-1692, 1997.
67. Kamel EM, Wyss MT, Fehr MK, et al: [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129:147-153, 2003.
68. Lin WY, Tsai SC, Cheng KY, et al: Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer—Taiwanese experiences. Cancer Invest 20:725-729, 2002.
69. Kim TS, Moon WK, Lee DS, et al: Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 25:829-834, 2001.
70. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, et al: Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2:229-234, 2001.
71. Grahek D, Montravers F, Kerrou K, et al: [18F]FDG in recurrent breast cancer: Diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 31:179-188, 2004.
72. Gallowitsch HJ, Kresnik E, Gasser J, et al: F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: A comparison to conventional imaging. Invest Radiol 38:250-256, 2003.
73. Fueger BJ, Weber WA, Quon A, et al: Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 7:369-376, 2005.
74. Moon DH, Maddahi J, Silverman DH, et al: Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39:431-435, 1998.
75. Radan L, Ben-Haim S, Bar-Shalom R, et al: The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107:2545-2551, 2006.
76. Suárez M, Pérez-Castejón MJ, Jiménez A, et al: Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46:113-121, 2002.
77. Weir L, Worsley D, Bernstein V: The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 11:204-209, 2005.